Renin-angiotensin-aldosterone system inhibition is a central component in the management of patients with chronic kidney disease (CKD) who have albuminuria. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) decrease albuminuria, reduce cardiovascular events, and slow progression of CKD.1 KDIGO guidelines recommend use of ACEi or ARB for adult patients with CKD and severely increased albuminuria (>300mg/24h) and suggest their use for diabetic or hypertensive patients with moderately increased albuminuria (30-300mg/24h).